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oxygen supply to the skeletal muscles. However, it is not entirely clear if they play an equally important role during the course of PPH from early to end-stage. The multifactorial cause is not unique to PPH, but similar alterations in inspiratory and peripheral muscles have been found in patients with chronic obstructive pulmonary disease (COPD) and chronic heart failure. 3 Several studies have demonstrated the benefit of exercise training, in addition to standard pharmacological treatment, on exercise capacity, peak oxygen capacity, and quality of life. 4 Specifically, exercise training improved skeletal muscle dysfunction by increasing the number of capillaries per muscle fibre and by improved oxidative enzyme activity after a 12-week exercise programme resulting in increased quadriceps endurance. 5 These studies underline the fact that peripheral factors contribute to the limited exercise capacity, but are, at least in part, reversible. As it takes some time before exercise training achieves these positive effects, interventions with immediate effects, and by alternative mechanisms, are desired. In this issue of the journal, Ulrich and colleagues provide evidence that normobaric hyperoxia may acutely improve exercise capacity. 6 This is interesting, from both a therapeutic and a pathophysiological point of view. They present data from a randomized, sham-controlled, single-blinded, crossover trial on the effect of oxygen-enriched air on exercise performance. Twenty-two patients with pulmonary arterial hypertension (PAH)/chronic thrombo-embolic pulmonary hypertension (CTEPH), with a resting PaO 2 > _7.3 and arterial oxygen desaturation during exercise were included. Patients underwent four exercise tests; two exercise tests with a progressive ramp protocol and two exercise tests with a constant workload protocol. Exercise performance clearly improved if patients were tested during receipt of oxygen-enriched air (FiO 2 0.50) as compared with ambient air (FiO 2 0.21). The protocol is thorough and clear, and has recently been validated in healthy volunteers by the same group. 7 As far as we are aware, this paper is the first to study the mechanisms by which normobaric hyperoxia improves exercise performance in PPH patients. The authors provide detailed analysis of gas exchange, which may help to understand the reason(s) for the improvement in exercise capacity during hyperoxia, but possibly also the limiting factors in normoxia. Normobaric hyperoxia increased cerebral and quadriceps muscle oxygen saturation, thereby oxygen availability to peripheral muscles and cerebral motor and sensory neurons. Thus, normobaric hyperoxia could improve skeletal muscle efficiency; however, detailed skeletal muscle characterization is needed to confirm this. Interestingly, cerebral regulation of dyspnoea perception seems to be important and may be a limiting factor of exercise capacity in healthy subjects as very recently shown by the same group. What are the clinical implications of this study? Should we consider supplemental oxygen a standard therapy for PPH patients or just as add-on to optimize therapy, for instance during exercise training? Will the clinical improvement sustain over time? Does it also apply to the important group of patients with PPH and underlying connective tissue disorders where interstitial lung disease and alveolar damage is a crucial factor? Also is there a down-side to prolonged use of hyperoxic therapy? Thus, several questions have to be answered before we can consider it current practice.
It is important to note that the population Ulrich et al. included in their study was not severely limited, having a normal cardiac output at rest and an only mildly reduced 6-min walking distance. 6 Patients had normal oxygen levels at rest and desaturated during exercise; measured SpO 2 at the end of the 6-min walk test was 89 ± 5%. Do patients who desaturate to 94% or 80% benefit equally to patients who desaturate to 85%? It is possible that limitations of exercise capacity or the effects of hyperoxia differ between early and more advanced PPH. It is generally thought that an inadequate increase in cardiac output during exercise is a central factor of reduced exercise capacity in patients with PPH. The observation that maximal heart rate increased during hyperoxia in PPH patients, but not in healthy subjects, 7 argues against a primary cardiac limitation of exercise capacity. In fact, it suggests that there is some cardiac reserve or less dyspnoea sensation in at least these patients with mild to moderate PPH that is not completely exhausted during maximal exercise at normoxia. This is in line with previous arguments against limited cardiac output as the primary cause for reduced exercise capacity in a human model of acute pulmonary hypertension, which resembled findings in PAH very well. 8 To be potentially able to tailor therapy with respect to limiting factors of exercise capacity in different stages of PPH, it would be interesting to know the effects of hyperoxia on pulmonary arterial pressure and cardiac output during exercise, too. It would also be interesting to know if there is a dose-effect relationship and, if present, to what level of FiO 2 and as to whether it is linear or not. This may have practical consequences for the therapeutic use if the same could be achieved with lower FiO 2 . This would make this potentially interesting therapy less cumbersome as exercise is mainly performed outside home and is also less expensive. This question is also relevant for the pathophysiological understanding. Furthermore, it is possible that the maximal effect achievable with normobaric hyperoxia does not go in parallel for all factors that change (i.e. arterial, cerebral, and muscular oxygen saturation, haemodynamic factors, possibly pulmonary pressure, and cardiac output). This may help to define which of the different factors is most important for limiting exercise capacity. Interestingly, a study comparing COPD patients with healthy controls demonstrated that hyperoxia increased exercise endurance in a dose-dependent manner, up to an inspired oxygen fraction of 50%, in both COPD patients and healthy controls. 9 Still, in athletes, it seems to induce adaptive muscular changes but not performance. Should oxygen be given continuously during everyday activities, or just during exercise and during training? In COPD, oxygen is recommended during exercise if there is a reduction of SpO 2 < _88% during exercise, and guidelines suggest oxygen may even be warranted during exercise in those who do not desaturate but display ventilatory abnormalities, and supplemental oxygen may permit greater exertion/improve training. 10 Whether administration of oxygen in patients with hypoxaemia during exercise influences prognosis remains unknown, both for PPH and for COPD. The data of the study by Ulrich et al. suggest that hyperoxia is of value for daily life activities as time of constant workload could be more than doubled. 6 They are also in line with the guidelines on pulmonary hypertension that oxygen therapy is recommended if resting PaO 2 is low for symptomatic benefit and correctable oxygen desaturation during exercise despite scarcity of evidence to support these recommendations. 1 On the other hand, excessive supplemental oxygen can be deleterious although it has been proven to be valuable in many clinical situations. 1, 10 Thus, hyperoxia may cause vasoconstriction, in various vascular beds. 11 In acute heart failure, oxygen supplementation was found to reduce stroke volume and cardiac output and to increase pulmonary capillary wedge pressure (peripheral oxygen saturation 93% at normoxia). This effect was seen as early as 24% FiO 2 , equivalent to 1 L/min of supplemental oxygen. 12 Also, coronary vasospasms have been described under hyperoxia in various studies in patients with coronary artery disease. 13 Hyperoxia has been associated with cellular injury through increased production of reactive oxygen intermediates, promoting inflammatory response leading to tissue damage and/or apoptosis. 14 Besides causing parenchymal lung injury, hyperoxia may also increase pulmonary vascular resistance as observed in animal models. 15 To understand the balance between the beneficial and deleterious effects of hyperoxia is complex, also because the underlying mechanisms of PPH may differ. This is particularly true for patients with connective tissue disease. Clear data on possibly negative effects of oxygen in patients with PPH are not available yet. Moreover, one may argue that such potentially negative effects may be irrelevant if oxygen is given for a short period only. Potentially, higher training intensities could be reached that could induce adaptive changes seen in high-intensity training. Potentially beneficial and harmful effects in PPH of supplemental oxygen are summarized in Figure 1 . The study by Ulrich et al. suggests that the beneficial effects exceed the potentially harmful ones, at least if given during exercise in a fixed dose for a short period of time. 6 This is very promising for these patients, but many aspects remain uncertain. Therefore, dose and longer term effects of oxygen supplementation should be tested as a next step. Moreover, potential differences between underlying mechanisms of PPH should be investigated. In such trials, not only positive effects on exercise performance need to be tested, but also potentially harmful effects.
